Medicine and Dentistry
Encephalitis
100%
Pediatrics
88%
Receptor Antibody
72%
Dextro Aspartic Acid
54%
Immunotherapy
49%
Diseases
47%
Plasma Exchange
36%
Immunoglobulin
31%
Clinical Feature
30%
Modified Rankin Scale
29%
Rituximab
27%
Meta-Analysis
27%
Catatonia
27%
Allergic Encephalitis
27%
Paraneoplastic Cerebellar Degeneration
27%
Multiple Sclerosis
27%
Gene Linkage
27%
Disease
27%
Werdnig Hoffmann Disease
27%
Onasemnogene Abeparvovec
27%
Infusion
27%
N Methyl Dextro Aspartic Acid Receptor Antibody
23%
Myelin Oligodendrocyte Glycoprotein
20%
N Methyl-D-Aspartate Receptor
18%
Functional Status
18%
Disease Course
13%
Medical Record
13%
Clinician
12%
Cohort Analysis
11%
Epileptic Seizure
10%
Autoimmunity
10%
Intensive Care Unit
9%
Peripheral Nervous System
9%
Apheresis
9%
Recurrent Disease
8%
Disease Severity
7%
Cyclophosphamide
7%
Treatment Duration
7%
Spinal Muscular Atrophy
6%
Adverse Outcome
5%
Pediatrics Patient
5%
Rating Scale
5%
Prevalence
5%
Cerebrospinal Fluid
5%
Ganglioneuroblastoma
5%
Claustrum
5%
Glutamate Decarboxylase
5%
Hu Antibody
5%
Symptomatology
5%
Memory Disorder
5%
Immunology and Microbiology
Encephalitis
48%
Rituximab
47%
Receptor Antibody
45%
Autoimmunity
38%
Immunotherapy
35%
Limbic Encephalitis
27%
Autoimmune Encephalitis
27%
Multiple Sclerosis
27%
Onasemnogene Abeparvovec
27%
Intravenous Immunoglobulin
23%
Myelin Oligodendrocyte Glycoprotein
20%
Functional Status
18%
Apheresis
9%
Medical Record
8%
Hu Antibody
5%
Claustrum
5%
Blood Plasma
5%
Cerebrospinal Fluid
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
36%
Encephalitis
30%
Dextro Aspartic Acid
27%
Central Nervous System Disease
27%
Receptor Antibody
27%
Immunotherapy
27%
Werdnig Hoffmann Disease
27%
Onasemnogene Abeparvovec
27%
Diseases
21%
Rankin Scale
20%
Functional Status
18%
Immunoglobulin
18%
Adverse Event
10%
Disease Course
7%
Spinal Muscular Atrophy
6%
